Search

everythinglearnresearchcommunity

for

Search:↓

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Compound 4 is a promising treatment for hair loss with low toxicity.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Erlotinib can cause nonscarring hair loss and itchy skin.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Topical Ruxolitinib may safely treat severe hair loss.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.